With the sustained protection of HEMLIBRA,1–3 life can be beautifully spontaneous
Treated annualised bleed rate (ABR) was 1.5 for HEMLIBRA every week (1.5 mg/kg/QW) and 1.3 for HEMLIBRA every 2 weeks (3.0 mg/kg/Q2W) vs. 38.2 for episodic FVIII. Sustained mean trough plasma concentrations of HEMLIBRA were achieved across all doses (open-label studies).1–3
HEMLIBRA delivers sustained protection with the majority of patients achieving zero treated bleeds.1–3
Efficacy was maintained over time in patients receiving HEMLIBRA, across the HAVEN studies4
HEMLIBRA has a half-life of weeks, not hours1
Pharmacokinetics and MOA
HEMLIBRA was evaluated in HAVEN – an extensive clinical trial programme1-3,5,6
Consistent safety profile1
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing firstname.lastname@example.org or calling +44 (0)1707 367554. As HEMLIBRA® is a biological medicine, healthcare professionals should report adverse reactions by brand and batch number.
ABR, annualised bleed rate; FVIII, Factor VIII; MOA, mechanism of action; QW, every week; Q2W, every 2 weeks; TE, thrombotic event; TMA, thrombotic microangiopathy.
- HEMLIBRA Summary of Product Characteristics.
- Mahlangu J et al. N Engl J Med 2018;379:811-22.
- Oldenburg J et al. N Engl J Med 2017;377:809-18.
- Callaghan M et al. ISTH 2019: OC60.2.
- Young G et al. Blood 2019;134:2127-38.
- Pipe S et al. Lancet Haematol 2019;6:e295-38.
Date of preparation: August 2020